Patients’ selection and trial matching in early-phase oncology clinical trials-Reference-Cited by-同舟云学术

Patients’ selection and trial matching in early-phase oncology clinical trials

Published:2024-04 Issue: Volume:196 Page:104307
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Corbaux P.,Bayle A.,Besle S.,Vinceneux A.,Vanacker H.,Ouali K.,Hanvic B.,Baldini C.,Cassier P.A.,Terret C.,Verlingue L.

Funder

European Regional Development Fund

Publisher

Elsevier BV

Reference106 articles.

1. Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place;Adashek;NPJ Precis Oncol.,2023

2. Improving patient selection for immuno-oncology phase 1 trials: external validation of six prognostic scores in a French cancer center;Al Darazi;Int. J. Cancer,2021

3. Profile and outcome of cancer patients enrolled in contemporary phase I trials;Alouani;Eur. J. Cancer,2023

4. American Society of Clinical Oncology, 2023. Targeted Agent and Profiling Utilization Registry (TAPUR) Study [Internet]. clinicaltrials.gov [cited May 25, 2023]. Report No.: NCT02693535. Available at: 〈https://clinicaltrials.gov/ct2/show/NCT02693535〉.

5. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience;Arkenau;Br. J. Cancer,2008

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Artificial intelligence in oncology: ensuring safe and effective integration of language models in clinical practice;The Lancet Regional Health - Europe;2024-11